Filtered By:
Drug: Proton Pump Inhibitors PPIs
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 238 results found since Jan 2013.
Does proton pump inhibitor reduce the antiaggregant efficacy of aspirin in ischemic stroke?
Acta Neurol Taiwan. 2023 Mar 30;32(1):9-15.NO ABSTRACTPMID:36474449
Source: Acta Neurologica Taiwanica - December 7, 2022 Category: Neurology Authors: Tu ğba Özel Ali Ünal Sebahat Özdem Babur Dora Source Type: research
Impact of Rabeprazole on APO-Dabigatran Exposure in Healthy Volunteers
CONCLUSIONS: When APO-dabigatran is administered with rabeprazole, the exposure to dabigatran is reduced by about 30%, which is similar to the level observed with Pradaxa when it was co-administered with a proton pump inhibitor. However, the finding that one-third of participants had a > 50% reduction in exposure is concerning, and it highlights the need for caution in patients who have, or are at risk of, reduced gastric acidity.PMID:36700178 | PMC:PMC9869351 | DOI:10.1016/j.cjco.2022.09.006
Source: Atherosclerosis - January 26, 2023 Category: Cardiology Authors: Noel Chan Matt Wheeler Vinai Bhagirath Jacqueline Bosch Jutta Heinrich-Nols Debbie Sloane Joanne van Ryn Linda Jefferies Jacqueline Wilkinson Qilong Yi John Eikelboom Source Type: research
A nomogram for predicting major gastrointestinal bleeding in patients treated with rivaroxaban
CONCLUSION: The nomogram demonstrated good discrimination, calibration, and clinical applicability. Therefore, it could accurately predict the risk of MGIB in patients treated with rivaroxaban.PMID:37317530 | DOI:10.1080/00365521.2023.2220460
Source: Scandinavian Journal of Gastroenterology - June 15, 2023 Category: Gastroenterology Authors: Haiyan Cao Hongyan Xu Min Zhu Xinglin Chu Zhihuan Zhang Yongqi Dong Source Type: research
< em > ABCG2 < /em > Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
CONCLUSION: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.PMID:37641689 | PMC:PMC10460569 | DOI:10.2147/DDDT.S417096
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Hamin Kim Tae-Jin Song Jeong Yee Dong-Hyeok Kim Junbeom Park Hye Sun Gwak Source Type: research
